PAD Profile : Hyaluronic acid - Osteoarthritis

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Hyaluronic acid - Osteoarthritis

PAD Profile : Hyaluronic acid - Osteoarthritis Important

Keywords :

Sodium hyaluronate, synovial fluid, synovial joint injections,

Brand Names Include :

Durolane, Euflexxa, Fermathron, Hyalgan, Orthovisc, Ostenil, Suplasyn, Synocrom, Synopsis, Hylan GF, Synvisc ONE, Monovisc, Orthovisc, Synolis,

Important Information :

ASPH rehumatology only - Ostenil, Viscoseal and Synvisc

Traffic Light Status

Status 1 of 1.

Status :

Red

Formulations :

Intra-articular injection

Trust Alignment :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

BNF NICE SPC

Comments :

No comments returned.

Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Type

Document

Review Date

Evidence Review

Hyaluronic Acid in osteoarthritis - Evidence review - Dec 2010

Committee Recommendations

Date

Committee Name

Narrative

06 June 2018

Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Prescribing Clinical Network (PCN), during the update of the persistant non-malignant pain guidelines, does not recommend intra-articular hyaluronic acid injection in line with NICE guidance CG177.

It may be suitable for individual patients for whom other pharmacological options have been intolerable or ineffective and who are unable to undergo surgery. Hyaluronic acid for these patients should be made available on an individual basis at the Acute Trust (this is not a Payment by Results Excluded drug and in individual cases GPs should not be asked to prescribe). (Discussed and agreed by PCN in January 2011)

Associated BNF Codes

No BNF codes returned.